PTC Therapeutics Inc SUNFISH Part 2 Risdiplam (RG7916) Results - Corporate Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the PTC Therapeutics call to review Part 2 of SUNFISH Clinical Trial Data at the SMA EU Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)
I would now like to hand the conference over to your speaker today, Head of Investor Relations, Alex Kane. Thank you. Please go ahead, sir.
Thank you, and hello, everybody. Welcome to the PTC Therapeutics conference call to review the SUNFISH Part 2 clinical trial data that was presented earlier today at the SMA Europe Conference.
Before we start, let me remind you that today's call will include forward-looking statements based on current expectations, including statements regarding the advancement of our joint collaboration program with Roche and the SMA Foundation and any related potential regulatory submissions, regulatory approvals or commercial prospects. These statements are subject to risks and to uncertainties that
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |